Iliac Stents Market Size

Market Outlook:

Iliac Stents Market size exceeded USD 926.9 Million in 2023 and is estimated to cross USD 1.47 Million by end of the year 2032, witnessing more than 5.2% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 926.9 Million
• CAGR (2024-2032): 5.2%
• Forecast Year Value (2032): USD 1.47 Million
• Historical Data Period: 2019-2023
• Largest Region: North America
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

1. Increasing prevalence of peripheral artery disease (PAD): PAD is a major driver of growth for the iliac stents market. As the global population ages and the rates of diabetes and obesity continue to rise, the prevalence of PAD is expected to increase, driving the demand for iliac stents.

2. Technological advancements in stent materials and designs: The continuous advancements in stent materials and designs are driving the growth of the iliac stents market. These advancements have resulted in the development of drug-eluting stents, bioresorbable stents, and improved stent deployment techniques, leading to higher success rates and lower rates of restenosis.

3. Growing demand for minimally invasive procedures: The increasing preference for minimally invasive procedures is a major growth driver for the iliac stents market. Minimally invasive procedures offer shorter hospital stays, faster recovery times, and reduced post-operative complications, leading to a higher demand for iliac stents.

4. Rising healthcare expenditure and infrastructure development: The increasing healthcare expenditure and infrastructure development in developing countries are creating significant growth opportunities for the iliac stents market. This growth is driven by the expansion of healthcare facilities, increased funding for medical research, and improved access to advanced medical technologies.

Industry

Report Scope

Report Coverage	Details
Segments Covered	Type, Artery Lesions, End-Use
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Abbott Laboratories, Alvimedica, Becton, Dickinson and Company, Biotronik, Boston Scientific, B. Braun, Cook, Getinge AB, iVascular, Medtronic Plc

1. Stringent regulatory requirements: The stringent regulatory requirements for the approval and commercialization of medical devices, including iliac stents, can act as a restraint on market growth. These requirements can lead to delays in product launches and increase the overall cost of development and commercialization.

2. Limited reimbursement policies: Limited reimbursement policies for iliac stent procedures in some regions can be a significant restraint on market growth. Patients may be deterred from undergoing stent placement due to high out-of-pocket costs, leading to lower demand for these devices.

3. Competition from alternative treatment options: The increasing availability and adoption of alternative treatment options, such as drug therapy and balloon angioplasty, can pose a challenge to the growth of the iliac stents market. Healthcare providers and patients may choose these alternative options over iliac stents, impacting market demand.